Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis
Authors:
Open Access
- 17 October 2012
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 1 (10) , 1-9
Abstract
Endometriosis is a gynecological condition resulting from proliferation of endometrial‐like tissue outside the endometrial cavity. Estrogen suppression therapies, mediated through gonadotropin‐releasing hormone (GnRH) modulation, decrease endometriotic implants and diminish associated pain albeit at the expense of bone mineral density (BMD) loss. Our goal was to provide model‐based guidance for GnRH‐modulating clinical programs intended for endometriosis management. This included developing an estrogen suppression target expected to provide symptomatic relief with minimal BMD loss and to evaluate end points and study durations supportive of efficient development decisions. An existing multiscale model of calcium and bone was adapted to include systematic estrogen pharmacologic effects to describe estrogen concentration‐related effects on BMD. A logistic regression fit to patient‐level data from three clinical GnRH agonist (nafarelin) studies described the relationship of estrogen with endometrial‐related pain. Targeting estradiol between 20 and 40 pg/ml was predicted to provide efficacious endometrial pain response while minimizing BMD effects.CPT: Pharmacometrics & Systems Pharmacology (2012) 1, e11; doi:10.1038/psp.2012.10; advance online publication 17 October 2012Keywords
This publication has 50 references indexed in Scilit:
- Coping with time scales in disease systems analysis: application to bone remodelingJournal of Pharmacokinetics and Pharmacodynamics, 2011
- Bone Physiology, Disease and TreatmentClinical Pharmacokinetics, 2010
- A physiologically based mathematical model of integrated calcium homeostasis and bone remodelingBone, 2010
- Pain scoring in endometriosis: entry criteria and outcome measures for clinical trials. Report from the Art and Science of Endometriosis meetingFertility and Sterility, 2010
- Estradiol Rates of Change in Relation to the Final Menstrual Period in a Population-Based Cohort of WomenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Estrogen‐TGFβ cross‐talk in bone and other cell types: Role of TIEG, Runx2, and other transcription factorsJournal of Cellular Biochemistry, 2007
- Effects of endogenous estrogen on renal calcium and phosphate handling in elderly womenAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Modeling the interactions between osteoblast and osteoclast activities in bone remodelingJournal of Theoretical Biology, 2004
- Runx2 Integrates Estrogen Activity in OsteoblastsJournal of Biological Chemistry, 2003
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trialThe Journal of Clinical Endocrinology & Metabolism, 1992